A Phase 1 interventional study of [14C]AZD4144 Solution for Infusion and [14C]AZD4144 Oral Solution in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabeled with a small amount of carbon-14 so it can be tracked in the body.
This study will take place at one site in Nottingham, United Kingdom, and will enroll 2 groups of 8 healthy men aged 30-65 years.
This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.
This study will take place at one site in Nottingham, United Kingdom.
It is planned to enroll 2 groups of 8 healthy men aged 30-65 years.
Each group will take part in 1 treatment period and receive a single dose of radiolabelled test medicine, either by injection into a vein or as a liquid by mouth. They'll stay in the clinic for up to 10 nights, attend 2 outpatient visits, and take up to 7 weeks to finish the study.
Blood and urine samples will be collected to do safety tests. Blood, urine and faecal samples will be collected to measure the amount of test medicine and its breakdown products.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Cohort 1 will receive a single intravenous injection of \[14C\]AZD4144 Solution for Infusion
Drug: [14C]AZD4144 Solution for Infusion
Participants in Cohort 2 will receive a single oral dose of \[14C\]AZD4144 Oral Solution
Drug: [14C]AZD4144 Oral Solution
Intravenous, fasted
Also known as: AZD4144
Oral, fasted
Also known as: AZD4144
Amount of AZD4144 excreted (Ae)
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (Fe)
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faeces and all excreta
Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted (CumAe)
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Cumulative amount of AZD4144 excreted expressed as a percentage of the radioactive dose administered (CumFe)
Mass balance recovery, rates and routes of elimination of total radioactivity of \[14C\]AZD4144 in urine, faecal and all excreta
Time frame: Urine and faecal samples collected from pre-dose until up to 216 hours post-dose
Area under the curve (AUC) of circulating plasma total radioactivity (TR) accounting for 10% or more of the dose
Identification of the chemical structure of each metabolite accounting for more than 10% by AUC of circulating total radioactivity
Time frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
80% or more of the radioactivity recovered in excreta
Identification of greater than 80% of the radioactivity recovered in the urine and/or faeces
Time frame: Plasma, urine and faecal samples from pre-dose until up to 216 hours post-dose
Time of maximum observed concentration (tmax) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Maximum observed concentration (Cmax) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Area under the curve from time 0 to the time of last measurable concentration (AUC0-t) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUCextrap) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Terminal elimination half-life (T1/2) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Apparent volume of distribution at steady state after a single IV administration (Vss) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Total body clearance calculated after a single IV administration (CL) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Renal clearance calculated using plasma AUC (CLR) for AZD4144 and total radioactivity
The PK of AZD4144 in plasma and urine, and total radioactivity in plasma and whole blood
Time frame: Plasma, urine and whole blood samples collected from pre-dose until up to 168 hours post-dose
Whole blood:plasma concentration ratios
Whole blood:plasma concentration ratios for total radioactivity
Time frame: Whole blood and plasma samples collected from pre-dose until 168 hours post-dose
Absolute bioavailability
Absolute bioavailability (F) of AZD4144 based on AUC0-inf
Time frame: Plasma samples collected from pre-dose until 168 hours post-dose
Plan to share: Yes — Qualified researchers can request access to anonymized individual participant-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Feb 2026 to primary completion in May 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD4144